HER2+ Breast Cancer | Specialty

Marvels in Medicine: Dr. Slamon on a Career of Drug Development in Oncology

February 8th 2021

Dennis J. Slamon, MD, PhD, discusses how his passion for medicine stemmed from a high school biology class, the struggle to develop trastuzumab as a viable drug in HER2-positive breast cancer, and the movie about his research that he didn’t want to see made.

Moving Metastatic Therapy to Early Stage Setting

February 5th 2021

Hormone Therapy in HER2+ Breast Cancer

February 5th 2021

Dr. Meisel on Sequencing Considerations in First- and Second-Line HER2+ Breast Cancer

February 3rd 2021

Jane L. Meisel, MD, discusses sequencing considerations in the first- and second-line settings of HER2-positive breast cancer.

De-Escalation of Adjuvant Anti-HER2 Therapy and Chemo

January 29th 2021

Adjuvant Systemic Therapy Data Updates

January 29th 2021

Metastatic Triple-Negative Breast Cancer

January 27th 2021

Metastatic Hormone Epidermal Growth Factor Receptor 2-Positive Breast Cancer

January 27th 2021

Metastatic Hormone-Receptor Positive Breast Cancer

January 27th 2021

Updated Data for Metastatic HER2+ Breast Cancer

January 25th 2021

Prognostic Tools for Early-Stage HER2+ Breast Cancer

January 25th 2021

Current Treatment Landscape for HER2+ Breast Cancer

January 25th 2021

Hurvitz Highlights Key Developments Made in Metastatic HER2+ Breast Cancer Paradigm

January 23rd 2021

Sara A. Hurvitz, MD, reflects on key pivotal trials and recent regulatory decisions that have propelled progress in metastatic HER2-positive breast cancer.

Trastuzumab Deruxtecan Approved in Europe for HER2+ Metastatic Breast Cancer

January 20th 2021

January 20, 2021 - The antibody-drug conjugate trastuzumab deruxtecan has been granted conditional approval in the European Union for use as a single agent in the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received 2 or more HER2-based regimens.

Adjuvant Systemic Therapy Decision Factors

January 20th 2021

HR-/HER2+ Early Stage Breast Cancer: Standards of Care

January 20th 2021

Refining Treatment Approaches for HER2+ Breast Cancer

January 20th 2021

A discussion on systemic treatment for HER2+ breast cancer and the impact of recent clinical trial data on decision making, including data discussed at the ESMO and SABCS 2020 Annual Meetings.

Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 2

January 14th 2021

Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1

January 13th 2021

Dr. Hurvitz on the Expanding Metastatic HER2+ Breast Cancer Treatment Arsenal

January 7th 2021

Sara A. Hurvitz, MD, discusses the expanding HER2-positive metastatic breast cancer treatment arsenal.